Status:

COMPLETED

Safety, Tolerability and Pharmacokinetics Study of CK-3773274

Lead Sponsor:

Corxel Pharmaceuticals

Collaborating Sponsors:

Cytokinetics

Conditions:

Obstructive Hypertrophic Cardiomyopathy

Healthy Adult Subjects

Eligibility:

All Genders

18-45 years

Phase:

PHASE1

Brief Summary

The purposes of this study are to: 1. Learn about the safety of CK-3773274 after a single dose and multiple doses in Chinese healthy adult subjects. 2. Learn how healthy subjects tolerate CK-3773274 ...

Eligibility Criteria

Inclusion

  • Healthy Chinese males and females between 18 and 45 years of age, inclusive
  • Body weight ≥50kg and body mass index (BMI) within 18 to 26 kg/m2, inclusive
  • Acoustic windows adequate for accurate transthoracic echocardiograms
  • Normal cardiac structure and function, as determined by the cardiologist, or if abnormalities are present, the finding is not clinically significant as determined by the cardiologist
  • LVEF ≥65 percent at screening, and LVEF ≥60 percent at Day-1
  • Normal ECG

Exclusion

  • History of stomach or intestinal surgery or resection that would potentially alter absorption and/or excretion of orally administered drugs
  • Subjects with breast implants that may impede echocardiography
  • A clinically significant illness within 4 weeks prior to admission to the CRU
  • Inability to swallow tablets
  • Use of alcohol-containing, grapefruit-containing, or caffeine-containing foods or beverages within 48 hours prior to admission to the CRU
  • Poor peripheral venous access
  • Any blood donation within 60 days prior to admission to the CRU, or any plasma donation within 30 days prior to admission to the CRU, or receipt of blood products within 2 months prior to admission to the CRU

Key Trial Info

Start Date :

April 10 2021

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

August 5 2021

Estimated Enrollment :

28 Patients enrolled

Trial Details

Trial ID

NCT04783766

Start Date

April 10 2021

End Date

August 5 2021

Last Update

January 24 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Clinical Site

Beijing, Beijing Municipality, China, 100032

Safety, Tolerability and Pharmacokinetics Study of CK-3773274 | DecenTrialz